3D Signatures Inc. announces clinical study results which confirm that based on a swab from the inside of a patient’s cheek, its proprietary TeloView™ software platform has the ability to identify patients with Alzheimer’s disease (“AD”) and, furthermore, distinguish between mild, moderate, and severe forms of the disease. The results of this confirmatory study have been accepted for publication in the peer-reviewed Journal of Alzheimer’s Disease.

Data from a new study1 published recently in Urologic Oncology involving men with localized high-risk prostate cancer suggests that the use of 3D Signatures Inc.'s technology platform, TeloView™, may be a promising blood-based treatment-response biomarker in prostate cancer patients who are undergoing combined (hormonal) androgen deprivation therapy and radiation therapy.

I wrote a check for $50,000 into 3D Signatures. That's because I believe that this $50,000 could soon be worth many times that. In fact, in just a bit, I'll show you why a 15,700% potential return is possible from here. And it all starts with a very special situation that could soon propel the shares of this Company.